[1]段茜,程燕,储蕾,等.银屑病与高血压病的相关性分析[J].中国皮肤性病学杂志,2015,(02):143-147.[doi:10.13735/j.cjdv.1001-7089.201404140]
 DUAN Xi,CHENG Yan,CHU Lei,et al.The Correlation between Psoriasis and Hypertension[J].The Chinese Journal of Dermatovenereology,2015,(02):143-147.[doi:10.13735/j.cjdv.1001-7089.201404140]
点击复制

银屑病与高血压病的相关性分析
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2015年02期
页码:
143-147
栏目:
论著
出版日期:
2015-02-01

文章信息/Info

Title:
The Correlation between Psoriasis and Hypertension
作者:
段茜12程燕3储蕾1王伟霞1张敏1
1.四川大学华西医院皮肤科,四川 成都610041;2.川北医学院附属医院皮肤科,四川 南充637000;3.成都市第二人民医院皮肤科,四川 成都 610041
Author(s):
DUAN Xi12CHENG Yan3CHU Lei1WANG Weixia1ZHANG Min1
1 Department of Dermatovenereology,West China Hospital,Sichuan University,Chengdu 610041,China;2.Department of Dermatology,The Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China;3.Department of Dermatovenereology,the Second People′s Hospital of Chengdu,Chengdu 610041,China
关键词:
银屑病银屑病性关节炎高血压病Meta分析
Keywords:
Psoriasis(PsO)Hypertension(HPN)Psoriatic arthritis (PsA)Metaanalysis
分类号:
R 758.63;R 544.1
DOI:
10.13735/j.cjdv.1001-7089.201404140
文献标志码:
A
摘要:
目的评价银屑病、银屑病性关节炎与高血压病的相关性。方法计算机检索多种数据库,评价纳入文献的质量及提取资料后,运用RevMan 5.0软件对符合标准的银屑病及银屑病性关节炎与高血压病相关性的研究进行Meta 分析。结果纳入关于银屑病与高血压病的文献共29篇,结果显示银屑病与高血压病具有相关性[OR=1.68,95%CI(1.50,1.87)]。轻度及重度银屑病与高血压病具有相关性[OR=1.27,95%CI(1.24,1.30)];[OR=1.48,95%CI(1.35,1.62)]。纳入关于银屑病性关节炎与高血压病的文献共7篇。银屑病性关节炎与高血压病具有显著相关性[OR=2.33,95%CI(1.44,3.76)]。结论在目前的数据支持下,无论银屑病严重程度,银屑病与高血压病均有相关性,银屑病性关节炎与高血压病有显著相关性。提示银屑病和银屑病性关节炎可能增加高血压病的患病风险。
Abstract:
ObjectiveTo assess the correlation between psoriasis(PsO)/psoriatic athritis(PsA) and hypertension(HPN),and the correlation between PsO and HPN basing on different severity and regions.MethodsWe searched database to collect studies of the association between PsO,PsA and HPN according to the criteria.Evaluate the quality of included studies,extracted data and performed metaanalyses by using the RevMan 5.0 software.ResultsA total of 29 studies on PsO and HPN were included in.The pooled analysis showed the PsO group associated with HPN [OR=1.68,95%CI(1.50,1.87)].The mild or severe PsO group associated with HPN[OR=1.27,95%CI(1.24,1.30)],[OR=1.48,95%CI(1.35,1.62)].The PsA group associated with HPN significantly[OR=2.33,95%CI(1.44,3.76)].ConclusionBased on the research data,regardless of PsO severity,PsO and HPN are correlated.The correlation also exists between PsA and HPN,suggesting that PsO or PsA may increase the risk of HPN.

参考文献/References:

[1] Sommer DM,Jenisch S,Suchan M,et al.Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis[J].Arch Dermatol Res,2006,298(7):321-328.
[2] Huerta C,Rivero E,Rodríguez LAG.Incidence and risk factors for psoriasis in the general population[J].Arch Dermatol,2007,143(12):1559.
[3] Chen YJ,Shen JL,Wu CY,et al.Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis[J].J Am Acad Dermatol,2009,60(2):225-230.
[4] 程燕,段茜,张敏,等.银屑病患者罹患冠心病的风险评估[J].中华皮肤科杂志,2012,45(9):627-630.
[5] Higgins JP,Collaboration GS.Cochrane handbook for systematic reviews of interventions[M].Wiley Online Library,2008:5.
[6] Armesto S,CotoSegura P,Osuna CG,et al.Psoriasis and hypertension:a casecontrol study[J].J Eur Acad Dermatol Venereol,2012,26(6):785-788.
[7] Neimann AL,Shin DB,Wang X,et al.Prevalence of cardiovascular risk factors i patient with psoriasis[J].J Am Acad Dermatol,2006,55(5):829-835.
[8] Shapiro J,Cohen AD,Weitzman D,et al.Psoriasis and cardiovascular risk factors:A casecontrol study on inpatients comparing psoriasis to dermatitis[J].J Am Acad Dermatol,2012,66(2):252-258.
[9] Naldi L,Chatenoud L,Belloni A,et al.Medical history,drug exposure and the risk of psoriasis[J].Dermatol,2008,216(2):125-132.
[10] Kimball A,Robinson D,Wu Y,et al.Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases[J].2001-2002.Dermatol,2008,217(1):27-37.
[11] Gerdes S,Zahl V,Knopf H,et al.Comedication related to comorbidities:a study in 1203 hospitalized patients with severe psoriasis[J].Brit J Dermatol,2008,159(5):1116-1123.
[12] Chen YJ,Wu CY,Shen JL,et al.Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome[J].Arch dermatol,2008,144(12):1571.
[13] Xiao J,Chen LH,Tu YT,et al.Prevalence of myocardial infarction in patients with psoriasis in central China[J].J Eur Acad Dermatol Venereol,2009,23(11):1311-1315.
[14] Wakkee M.Psoriasis:comorbidity and treatment[M].Erasmus University Rotterdam,2010.
[15] Driessen RJB,Boezeman JB,Kerkhof PC,et al.Cardiovascular risk factors in highneed psoriasis patients and its implications for biological therapies[J].J Dermatol Treat,2009,20(1):42-47.
[16] Takahashiemail H,Takahashi I,Honma M,et al.Prevalence of metabolic syndrome in Japanese psoriasis patients[J].J Dermatol Sci,2010,57(2):143-144.
[17] Schmitt J,Ford DE.Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors,but not with cardiovascular events in a population‐based sample[J].J Eur Acad Dermatol,2010,24(8):885-892.
[18] Nisa N,Qazi MA.Prevalence of metabolic syndrome in patients with psoriasis[J].Indian J Dermatol Venereol Leprol,2010,76(6):662-665.
[19] Cohen AD,Weitzman D,Dreiher J.Psoriasis and hypertension:a casecontrol study[J].Acta Derm Venereol,2010,90(1):23-26.
[20] Augustin M,Reich K,Glaeske G,et al.Comorbidity and agerelated prevalence of psoriasis:Analysis of health insurance data in Germany[J].Acta dermatovenereologica,2010,90(2):147-151.
[21] Almutairi N,Alfarag S,Almutairi A.Comorbidities associated with psoriasis:an experience from the Middle East[J].J dermatol,2010,37(2):146-155.
[22] Warnecke C,Manousaridis I,Herr R,et al.Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis:a case control study[J].Eur J Dermatol,2011,21(5):761.
[23] Mebazaa A,Asmi M E,Zidi W,et al.Metabolic syndrome in Tunisian psoriatic patients:prevalence and determinants[J].J Eur Acad Dermatol,2011,25(6):705-709.
[24] Love TJ,Qureshi AA,Karlson EW,et al.Prevalence of the metabolic syndrome in psoriasis:results from the National Health and Nutrition Examination Survey,2003-2006[J].Arch Dermatol,2011,147(4):419-424.
[25] Gisondi P,Tessari G,Conti A,et al.Prevalence of metabolic syndrome in patients with psoriasis:a hospitalbased casecontrol study[J].Brit J Dermatol,2007,157(1):68-73.
[26] Langan SM,Seminara NM,Shin DB,et al.Prevalence of metabolic syndrome in patients with psoriasis:a populationbased study in the United Kingdom[J].J Invest Dermatol,2012,132:556-562.
[27] Yang YW,Keller J,Lin HC.Medical comorbidity associated with psoriasis in adults:a population‐based study[J].Brit J Dermatol,2011,165(5):1037-1043.
[28] Prodanovich S,Kirsner RS,Kravetz JD,et al.Association of psoriasis with coronary artery,cerebrovascular,and peripheral vascular diseases and mortality[J].Arch Dermatol,2009,145(6):700.
[29] KayeJ,Li L,Jick SS.Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis[J].Brit J Dermatol,2008,159(4):895-902.
[30] Gelfand JM,Neimann AL,Shin DB,et al.Risk of myocardial infarction in patients with psoriasis[J].JAMA,2006,296(14):1735-1741.
[31] Henseler T,Christophers E.Disease concomitance in psoriasis[J].J Am Acad Dermatol,1995,32(6):982-986.
[32] Tam LS,Tomlinson B,TW Chu,et al.Cardiovascular risk profile of patients with psoriatic arthritis compared to controls the role of inflammation[J].Rheumatology,2008,47(5):718-723.
[33] Mok CC,Ko GT,Yin L,et al.Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis[J].Arthritis Res,2011,63(2):195-202.
[34] Han C,Robinson DW,Hackett MV,et al.Cardiovascular disease and risk factors in patients with rheumatoid arthritis,psoriatic arthritis,and ankylosing spondylitis[J].J Rheumatol,2006,33(11):2167-2172.
[35] Kimhi O,Caspi D,Bornstein NM,et al.Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis[J].Grune & Stratton.2007,12:102-104.
[36] Boehncke WH,Boehncke S,Tobin AM,et al.The ′psoriatic march′:a concept of how severe psoriasis may drive cardiovascular comorbidity[J].Exp Dermatol,2011,20(4):303-307.
[37] Armstronga AW,Stephanie VV,Armstrong EJ,et al.Angiogenesis and oxidative stress:common mechanisms linking psoriasis with atherosclerosis[J].J Dermatol Sci,2011,63(1):1-9.

相似文献/References:

[1]唐娟,张晓艳,宋佩华,等.寻常性银屑病患者皮损及外周血单一核细胞中IL-17A的表达[J].中国皮肤性病学杂志,2012,(08):689.
 TANG Juan,ZHANG Xiao-yan,SONG Pei-hua,et al.Expression of IL-17A in Involved Lesions and Blood Mononuclear Cells of Patients with Psoriaisis[J].The Chinese Journal of Dermatovenereology,2012,(02):689.
[2]戴莎,王秀丽,宋心葵,等.银屑病患者410例合并代谢综合征分析[J].中国皮肤性病学杂志,2012,(08):700.
 DAI Sha,WANG Xiu-li,SONG Xin-kui,et al.Analysis of 410 Cases of Psoriasis Patients with Metabolic Syndrome[J].The Chinese Journal of Dermatovenereology,2012,(02):700.
[3]谢韶琼,汪青良,宋勋,等.凉血润肤汤治疗寻常性银屑病42例疗效观察[J].中国皮肤性病学杂志,2012,(08):743.
 XIE Shao-qiong,WANG Qing-liang,SONG Xun,et al.Clinical Observation of Liangxierunfu Decoction on 42 Cases of Psoriasis Vulgaris[J].The Chinese Journal of Dermatovenereology,2012,(02):743.
[4]广维,朱红,姚树兰,等.伊那西普治疗银屑病的十年回顾[J].中国皮肤性病学杂志,2012,(08):745.
 GUANG Wei,ZHU Hong,YAO Shu-lan,et al.A 10-year Review of Etanercept in the Treatment of Psoriasis[J].The Chinese Journal of Dermatovenereology,2012,(02):745.
[5]史航,刘晓明,林熙然,等.银屑病发病与创伤愈合机制的比较[J].中国皮肤性病学杂志,2012,(08):748.
 SHI Hang,LIU Xiao-ming,LIN Xi-ran.A Comparison on Pathogenesis of Psoriasis and Mechanism of Wound Healing[J].The Chinese Journal of Dermatovenereology,2012,(02):748.
[6]刘晓洁,张峻岭,刘雪,等.头皮银屑病和脂溢性皮炎的皮肤镜特征分析[J].中国皮肤性病学杂志,2015,(01):36.[doi:10.13735/j.cjdv.1001-7089.2015.0036]
 LIU Xiao jie,ZHANG Jun ling,LIU Xue,et al.Analysis of Dermoscopic Criteria for Scalp Psoriasis and Scalp Seborrheic Dermatitis[J].The Chinese Journal of Dermatovenereology,2015,(02):36.[doi:10.13735/j.cjdv.1001-7089.2015.0036]
[7]王彩梅,汤洁,向志,等.甲损害在泛发性脓疱型银屑病中的临床意义[J].中国皮肤性病学杂志,2015,(01):44.[doi:10.13735/j.cjdv.1001-7089.2015.0044]
 WANG Cai mei,TANG Jie,XIANG Zhi,et al.Clinical Significance of Nail Involvement in Generalized Pustular Psoriasis[J].The Chinese Journal of Dermatovenereology,2015,(02):44.[doi:10.13735/j.cjdv.1001-7089.2015.0044]
[8]李珺莹,李红.酪氨酸激酶及其抑制剂与免疫性皮肤病的研究进展[J].中国皮肤性病学杂志,2015,(01):93.[doi:10.13735/j.cjdv.1001-7089.2015.0093]
 LI Jun ying,LI Hong.Tyrosine Kinases and its Inhibitors in Immune Dermatologic Diseases[J].The Chinese Journal of Dermatovenereology,2015,(02):93.[doi:10.13735/j.cjdv.1001-7089.2015.0093]
[9]杨颜龙,张禁,易松柏,等.阿维A胶囊联合复方甘草酸苷注射液治疗红皮病型银屑病30例临床观察[J].中国皮肤性病学杂志,2015,(02):217.[doi:10.13735/j.cjdv.1001-7089.201403167]
 YANG Yan long,ZHANG Jin,YI Song bai,et al.Clinical Observation of 30 Acitretin Capsules Combine with Compound Glycyrrhizin Injection in the Treatment of Patients with Erythrodermic Psoriasis[J].The Chinese Journal of Dermatovenereology,2015,(02):217.[doi:10.13735/j.cjdv.1001-7089.201403167]
[10]孙景英,普雄明,吴卫东.CXCL9和Smad3在新疆维吾尔族寻常性银屑病患者皮损中的表达[J].中国皮肤性病学杂志,2015,(03):242.[doi:10.13735/j.cjdv.1001-7089.201407083]
 SUN Jing ying,PU Xiong ming,WU Wei dong.The Expression of CXCL9 and Smad3 in Psoriasis Vulgaris of Xinjiang Uyghur Patients[J].The Chinese Journal of Dermatovenereology,2015,(02):242.[doi:10.13735/j.cjdv.1001-7089.201407083]

更新日期/Last Update: 2015-02-25